A Study of IBI311 in Subjects With Active Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Biological: IBI311Biological: placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT05795621
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05793450
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT05792917
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, China
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05774873
- Locations
- 🇦🇺
Westmead Hospital, Waratah, New South Wales, Australia
A Study of IBI351 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05699993
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study of IBI351 in Healthy Subjects
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05688124
- Locations
- 🇨🇳
the First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05653180
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05645627
- Locations
- 🇨🇳
Shanghai Skin Disease Hospital, Shanghai, Shanghai, China
Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: IBI333
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT05639530
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 368
- Registration Number
- NCT05636215
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
🇦🇺Sunshine Coast University Private Hospital, Sunshine Coast, Queensland, Australia